Results 31 to 40 of about 21,937,235 (349)

Linking contact tracing with genomic surveillance to deconvolute SARS-CoV-2 transmission on a university campus

open access: yesiScience, 2022
Summary: Contact tracing and genomic data, approaches often used separately, have both been important tools in understanding the nature of SARS-CoV-2 transmission.
Jacquelyn Turcinovic   +10 more
doaj   +1 more source

Implementing the EffTox dose-finding design in the Matchpoint trial [PDF]

open access: yes, 2017
Background: The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation phase.
Billingham, Lucinda   +5 more
core   +4 more sources

Publication bias in clinical research.

open access: yesThe Lancet, 1991
In a retrospective survey, 487 research projects approved by the Central Oxford Research Ethics Committee between 1984 and 1987, were studied for evidence of publication bias.
P. Easterbrook   +3 more
semanticscholar   +1 more source

Obstruction of Small Arterioles in Patients with Critical Limb Ischemia due to Partial Endothelial-to-Mesenchymal Transition

open access: yesiScience, 2020
Summary: Critical limb ischemia (CLI) is a hazardous manifestation of atherosclerosis and treatment failure is common. Abnormalities in the arterioles might underlie this failure but the cellular pathobiology of microvessels in CLI is poorly understood ...
Jacqueline Chevalier   +13 more
doaj   +1 more source

Stochastic Approximation and Modern Model-Based Designs for Dose-Finding Clinical Trials

open access: yes, 2010
In 1951 Robbins and Monro published the seminal article on stochastic approximation and made a specific reference to its application to the "estimation of a quantal using response, nonresponse data." Since the 1990s, statistical methodology for dose ...
Cheung, Ying Kuen
core   +1 more source

Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma. [PDF]

open access: yes, 2017
Intratumoral heterogeneity (ITH) is a prominent feature of kidney cancer. It is not known whether it has utility in finding associations between protein expression and clinical parameters. We used ITH that is detected by immunohistochemistry (IHC) to aid
Devarajan, Karthik   +10 more
core   +3 more sources

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

open access: yesJournal of Clinical Medicine, 2019
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed ...
L. Cavagna   +113 more
semanticscholar   +1 more source

Pearson’s patterns correlational of clinical risks at admissions with hospitalization outcomes during initial COVID-19 outbreak

open access: yesiScience, 2022
Summary: COVID-19 outbreaks have crushed our healthcare systems, which requires clinical guidance for the healthcare following the outbreaks. We conducted retrospective cohort studies with Pearson’s pattern-based analysis of clinical parameters of 248 ...
Jingwen Li   +13 more
doaj   +1 more source

Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

open access: yes, 2010
Traditionally, the major objective in phase I trials is to identify a working-dose for subsequent studies, whereas the major endpoint in phase II and III trials is treatment efficacy. The dose sought is typically referred to as the maximum tolerated dose
Rogatko, André, Tighiouart, Mourad
core   +1 more source

Definition of valid proteomic biomarkers: a bayesian solution [PDF]

open access: yes, 2009
Clinical proteomics is suffering from high hopes generated by reports on apparent biomarkers, most of which could not be later substantiated via validation.
C.C. Holmes   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy